In recent times, antiepileptic drug (AED) development has expanded with at least seven new AEDs being marketed in a variety of countries. However, in this same period there have been very few trials of new AEDs in the developing world where the majority of people with epilepsy reside. There are many problems with the extrapolation of results from AED trials in developed countries, thus underlining the need for new AED trials in developing countries. This, however, presents a number of ethical and logistical problems, as the majority of people with epilepsy in developing countries are inadequately treated with established drugs. Additionally, there are further problems involving the cost of treatment and the allocation of sparse resources. If trials of new AEDs are to take place in developing countries, strict ethical guidelines must be adhered to, the trials must not be purely marketing exercises, and there must be the continued availability of the new AED to those in the trials who have benefited.
INTRODUCTION
In a medline review of articles on new antiepileptic drugs (AEDs) published over the last five years, we were only able to identify two trials that had taken place in developing countries. One of these trials was a double-blind study of progabide as add-on in refractory epilepsy in Uruguay', the other was a 'field study' of vigabatrin in Brazil*. There was one further trial of vitamin E in India, which was a double-blind add-on trial showing no advantage of vitamin E over placebo3. In this same period at least seven new antiepileptic drugs-felbamate, gabapentin, lamotrigine, oxcarbazepine, progabide, vigabatrin and zonisamide-have been licensed around the world (including developing countries). This lack of reported trials of new AEDs in developing countries raises a number of questions, particu-larly as the majority of patients with epilepsy world-wide are in the so-called third world countries. Unreported trials of new AEDs are taking place, but these trials are not subject to international scrutiny, and, as will be seen, this presents its own problems, as some of these trials may be no more than marketing ploys. There are several considerations in deciding whether AED trials, particularly of novel compounds, should be carried out in developing countries. The first is to address the magnitude of the problem of epilepsy in developing countries in terms of its epidemiology, response to treatment and social impact. The second consideration is the extent to which results from AED trials in developed countries can be extrapolated to developing countries. The third consideration is the logistics of carrying out AED trials in developing countries, and lastly there are the ethical aspects of drug trials in developing countries.
EPILEPSY IN DEVELOPING COUNTRIES-MAGNITUDE OF THE PROBLEM
It is generally accepted that the incidence of epilepsy in the developed world is around 50/1000OO/year. There have been few satisfactory studies of incidence rates of epilepsy in developing countries. Only five studies have reported incidence rates and these have varied between 35/1OOOOO/year in China4 and 230/100 OOO/year in Ecuado?.
A rate of 73/1OOOOO/year has been reported from Tanzania6 but there was a large intra-regional variation. A rate of 114/100 OOO/year from Chile' and between 122 and 190/100000/year from an Andean region of Ecuador' have been reported. Thus, apart from the results of the Chinese study, all other studies in developing countries suggest a higher incidence of epilepsy than in developed countries. There are more data available on prevalence rates of epilepsy than on incidence. The former are more easily obtained than the latter as smaller numbers are needed and cross-sectional designs can be used. There are large variations in the prevalence rates reported from the developing world from rates as low as 2.3/1000g to as high as 57/100010. Most surveys have, however, reported rates within a much narrower band, 4.4 to 19/100011-14. Large reliable population-based studies have been in the lower end of the spectrum15. Studies in the upper end of the spectrum are usually small scale surveys in geographic isolates and thus should be treated with caution". If prevalence rates are higher in developing countries, this probably relates to the younger age of the populations, the different aetiological profiles, and socioeconomic factors16.
Studies in four developing countries, Ecuador, Kenya, the Philippines and Pakistan, have shown that only a small proportion of patients (8-20%) with active epilepsy is at any one time actually receiving drug treatment16. Yet, in both the developed and developing world, control of seizures with monotherapy with a variety of AEDs can be achieved in about 60-80% of patients". This, however, still leaves approximately 20% who require polytherapy, and a large proportion of these will be resistant to present AEDs. Furthermore side-effects are a major cause for the failure of treatment", and thus new AEDs that have better side-effect profiles may be better tolerated.
It has been assumed that side-effects are not such an important issue in developing countries, but this is probably a misconceived perception16.
The social impact of epilepsy in the developed world is without question large, and indeed the indirect cost of epilepsy to society far outweighs the medical cost'*. In developing countries the social impact of epilepsy is also great. The social stigma, the inability of people with poorly controlled epilepsy to work, the hazards (in some countries epilepsy is called the 'burn disease') and the social disadvantages are probably even more important than in the developed world16. The indirect cost, however, is likely to be smaller whilst the medical costs of drug treatment are likely to be similar. In some cases medical costs may exceed the indirect social costs. Thus although in developing countries, hospital and clinical studies have shown that epilepsy is one of the commonest problems seen in outpatient clinicslg, epilepsy, as with other chronic diseases, generally carries a low priority for health care provision, which tends to be directed to acute, infectious and more life threatening conditions. Thus it is necessary to show that medical intervention for epilepsy can be successful and improve quality of life for scarce resources to be allocated2'.
EXTRAPOLATION OF TRIALS FROM THE DEVELOPED WORLD Efficacy
Although well-studied in the developed world, there have been few carefully monitored, prospective studies of AED efficacy in the developing world. This is important as many people with epilepsy in developing countries have had their condition for long periods before treatment is made available, a situation very different from that in most developed countries, with welldeveloped health economies21"2. It has been proposed that patients whose epilepsy is left untreated will become increasingly intractable"*24, and thus that patients in the developing world may prove to be more refractory than those in the developed world. This does not, however, appear to be the case, and the response to treatment of previously untreated populations in the developing world is probably similar to that in the developed world21,".
Another aspect that can affect the response of epilepsy to antiepileptic drugs is the different spectrum of aetiologies of epilepsy in the developing world. This is especially so for infectious causes, which are commoner in developing countries "jJ5. Because of the lack of diagnostic tools and manpower in developing countries, these causes are not always identified, yet may greatly affect the prognosis and response to treatment of the epilepsy. For example, it has been suggested that epilepsy due to cystercercosis (a common cause of epilepsy in the developing world) responds well to treatment with cysticidal therapy, but those who do not receive this therapy have a poor response to AED treatment26T27. At present, new AED trials in developed countries are carried out in patients classified by the type of seizure, and subdivision by aetiology is avoided. Thus, these trials should not be extrapolated to developing countries in which there is a different spread of aetiologies with possibly different responses to AED treatment.
Side-effects
The side-effects of AEDs consist of those that are objectively reported by the physician (e.g. ataxia, nystagmus) and those that are subjectively reported by the patient (e.g. unsteadiness, drowsiness). In most drug trials, it is the latter that make up most of the reported adverse events. The emphasis laid upon many side-effects is dependent upon social and cultural influences, and thus would be expected to differ from one community to another and from rural to urban societies.
There are also genetic and dietary influences in the incidence of specific side-effects. This has been well documented for zonisamide. Trials of zonisamide were abandoned in Europe and the U.S.A. due to a high incidence of kidney stones (4%), yet this side-effect has been seen in only one of over 2000 patients treated in Japan*'.
Pharmacokinetics
The pharmacokinetics of AEDs can be influenced by both genetic and environmental factors. Genetic polymorphism has been well described for the metabolism of phenytoin, and as a result phenytoin kinetics may not only vary from country to country, but even in sub-populations within one country*'"'. Furthermore different formulations available in different countries can also affect the pharmacokinetics31.
Other factors that play a prominent role are the prevalence of renal and hepatic diseases which affect the elimination of drugs, and gastrointestinal disease which affects the absorption. Furthermore population pharmacokinetics are partly determined by the age range and spread of that population (for example the clearance of gabapentin decreases with age due to an age-related decrease in creatinine clearance3*. The age range and spread of populations in developing countries are very different from those in developed countries16.
PROBLEMS OF DRUG TRIALS IN DEVELOPING COUNTRIES Recruitment and running a drug trial
The recruitment of patients into AED trials is likely to encounter many problems. As previously mentioned, the majority of patients in the developing world are not receiving AED therapy. The reasons for this failure of treatment are complex, and may involve non-pharmacological aspects such as cultural attitudes to epilepsy, acceptability of drugs for treatment, the cost of treatment, and less well-developed systems for the delivery of health care. All these will similarly affect patient recruitment to AED trials, but the last point has even wider implications.
In most developing countries there is a chronic lack of trained medical manpower, and this is more noticeable in rural areas. A recurring recommendation to cope with this is to use health workers to treat patients at a community health care leve133"5. This could lead to problems in correctly diagnosing epilepsy, determining the type of epilepsy and the aetiology. This problem is further compounded by the lack of imaging and EEG facilities in these countries.
Furthermore, it is incorrect to consider a country as a homogeneous group of people, and nowhere is this emphasized more than in the developing countries where there is often a great divide between rich and poor not only in terms of money and education but also occasionally in terms of race. Antiepileptic drug trials carried out in these countries are more likely to involve the rich minority than the poor majority, both for logistical and political reasons.
Ethics
The first and foremost ethical consideration is the criteria that should be used for inclusion in trials of new AEDs. The criteria that are used in the developing world should be the same as those in the developed world, and initially new AEDs should only be tried as add-on in patients with epilepsy that is resistant to available AEDs. This, however, immediately presents a logistical problem in that the majority of AEDs commonly available in developed countries are not accessible in developing countries. Thus the restriction that must apply is that the epilepsy is resistant to AEDs that are accessible in the country in which the trial is taking place. Developing countries do, however, present a good opportunity to try new AEDs in drug-ndive patients*', but ethically, this should only be done with those drugs that have reached a similar stage in developed countries.
Another problem is the expense of the drug. It is unethical to withdraw a new AED that has been very effective in a patient entered into a drug trial. In most drug trials, patients who have responded to a new AED can continue that drug in continuation trials or on a named patient basis, and when the drug is licensed the drug is usually then paid for by the health care system of that country. In developing countries, it is unreasonable to expect underfunded health care systems to finance the continuation of a new and expensive AED by patients entered into trials. This expense should be entirely met by the drug company funding the research for the period that the drug remains efficacious in each patient (for life, if necessary). This is paramount if short-term 'trials' of new AEDs that are just used to sell the AED to the participating patients are to be avoided. The expense of new AEDs has wider implications.
Only the minority of patients with active epilepsy in the developing world are receiving AED treatment, and it is likely that education and improved resources would greatly affect the prognosis of epilepsy in these communities*'.
Within this context, the use of newer more expensive AEDs is difficult to justify. Although in developed countries the indirect costs of epilepsy far outweighs the costs of medical treatmenti8, in financial terms in developing countries this may not be the case and is most certainly not the case when considering the use of new AEDs for which the cost of a year's treatment may exceed the national average wage. This calls into question the whole concept of AED trials especially trials of new AEDs in developing countries, as, regardless of the finding of these trials, the AEDs may not be affordable. Furthermore, the use of limited resources by governments in the developing world to fund AEDs that may have marginal benefits over much cheaper established AEDs such as phenobarbitone or phenytoin should perhaps have less priority than the use of these resources to tackle the preventable causes of epilepsy or the distribution of AEDs. Unless the newer AEDs are made available to the developing world at a considerable discount, it is difficult to justify the distribution of new AEDs to those countries regardless of the results of these trials.
CONCLUSIONS
The developing world contains a large population of people with epilepsy, most of whom are inadequately treated. Yet even given AED treatment, there will still be a significant number who are resistant to established AEDs. There is thus a need for new AED development in these countries. Because of the different demographics and aetiologies of the epilepsies, the results of new AED trials from the developed world cannot be simply extrapolated to the developing world, and thus drug trials are necessary. There are, hpwever, many logistical and ethical problems in carrying out these trials. Eventually, the problem of expense remains, and this is the dichotomy-AED trials in developing countries are on the one hand necessary for improved treatment in these countries, especially since surgical treatment is not available, and on the other hand, new AEDs cannot be afforded by these countries.
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